MYRG vs COGT Comparison

MYR Group Inc is a U.S. based holding company of specialty electrical construction service providers. Through its subsidiaries, it serves electric utility, commercial, and industrial construction markets in the United States and Canada, offering services such as design, engineering, procurement, construction, upgrades, maintenance, and repair, with a focus on construction, maintenance, and repair work. The company operates through two segments: Transmission and Distribution (T&D) and Commercial and Industrial (C&I). The majority of revenue is derived from the T&D segment, which provides a range of services on electric transmission and distribution networks and substation facilities, which include design, engineering, procurement, construction, upgrade and maintenance and repair services.

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.